• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Promising Results Seen in Lung Cancer Trials

Promising Results Seen in Lung Cancer Trials

September 26, 2007
CenterWatch Staff

Merck KGaA reported positive long-term results from a phase II trial of Stimuvax for the treatment of non-small cell lung cancer (NSCLC). The drug is a MUC-1 peptide-based liposomal vaccine, for the potential  treatment of cancers.

This study enrolled 171 subjects with stage IIIB/IV with stable or responding disease after any first-line chemotherapy with or without radiotherapy. The subjects were stratified by disease stage then randomized to receive Stimuvax plus best supportive care (BSC) or BSC alone.

The subjects in the Stimuvax arm received a single intravenous dose of cyclophosphamide 300mg/m2 followed by eight weekly subcutaneous immunizations with Stimuvax (1,000 mg).Although the overall study results did not reach statistical significance, the subjects with stage IIIB cancer receiving Stimuvax showed a median survival of 30.6 months compared with 13.3 months in the control group. At the three year follow-up, 49% of subjects who were treated with Stimuvax were still alive compared with 27% treated with BSC alone, representing a 45% reduction in mortality.

Based on the results, Merck KGaA is currently conducting a phase III trial of Stimuvax for the treatment of stage IIIA or IIIB NSCLC. Merck KGaA and Edmonton-based biotech Biomira entered into a development and commercialization licensing agreement for Stimuvax.

---

Also Pfizer released positive preliminary results from a phase II trial of sunitinib (Sutent), a multi-kinase inhibitor for the treatment of NSCLC. Sunitinib is already approved for the treatment of gastrointestinal tumors and renal cell carcinoma.

The trial was designed to compare sunitinib (37.5 mg/day) in combination with erlotinib (150 mg/day) in previously treated subjects with advanced NSCLC. The primary endpoint was safety and tolerability. Secondary endpoints included anti-tumor activity. The combination treatment was generally safe and well tolerated, with all adverse events mild to moderate in nature.

Two subjects had partial response; one which was maintained for more than three months and one which was currently ongoing. In addition, stable disease up to or more than 16 weeks was observed in two subjects. The randomized portion of this trial is currently underway.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing